Around here we like to take a little breather after distributing the quarterly Trend Analysis; response to the 2Q10 report has been very positive – many thanks – now it is time to get back after it, so expect to see the 3Q10 deals come barreling in starting next week. Now for informal poll time…With [...]

Hot off the press! The 2Q10 OnBioVC Trend Analysis study is available for download [HERE]; and now features OnBioIPO and OnBioM&A data too!
The 2Q10 OnBioVC Trend Analysis tracked, in aggregate, 81 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling $1,664.2M. Compared to 1Q10 OnBioVC data, this investment activity represents an increase in the [...]

It is always an exciting opportunity to report on new fund closings. In this case you may have already heard of Boston-based SV Life Sciences who recently closed their oversubscribed (yes, oversubscribed its $400M target close by some $100M+) $523M Fund V.
A few years ago I met peHub Editor-at-Large extraordinaire Dan Primack, who went [...]

“It is not birth, marriage or death but gastrulation, which is truly the most important time in your life.”
- Lewis Wolpert
UPDATE
OnBioVC, an Indicium Data company, is excited to announce that a satellite office has opened at Harvard Square in Cambridge, MA! If you are in the neighborhood (or anywhere in the greater Boston vicinity) I [...]

• View 1 Comment...

NEW FUNDS
Not much to report on in terms of new bioscience fund closings however, something to keep an eye on is the planned reported estimated $250M HealthCare Ventures Fund IX whose Form D was filed last week.
GOT CASH?
If you have not been paying attention lately, perhaps this will jar something loose $1BILLION IN CASH [...]

Hot off the press! The 1Q10 OnBioVC Trend Analysis study is available for download [HERE]; and now features OnBioIPO and OnBioM&A data too!
The 1Q10 OnBioVC Trend Analysis tracked, in aggregate, 74 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling $1,260.1M. Compared to 1Q09 OnBioVC data, this investment activity represents a decrease in the number [...]

Veryan (United Kingdom) a clinical-stage medical device company focused on a three dimensional vascular stent for peripheral vascular disease, closed a $5.4M series B financing. Participants include Seroba Kernal, Imperial Innovations, Oxford Capital Partners and NESTA.

The ‘Looking for Some (More) of This?’ series is focused upon the tracking of newly formed venture funds who are financing biomedical innovation.
Is it just me or are there some mixed signals here? Is the sky falling, LP’s running for the exits and new capital simply a figment of the imagination or did Boston-based Riverside [...]

Kosmos Biotherapeutics (Cambridge, MA) a preclinical-stage biopharmaceutical company developing an astrobiological therapeutic platform focused on the treatment of post-evolutionary disease in zero-gravity celestial settings, closed a whopping $319M Series A financing. Participants include Apple Ventures, Omniscient Venture Partners, Clairvoyant Capital, NASA Bioventures and Crystal Ball Ventures.
_________________________________________________________________________
Wishing you a happy April Fool’s
And no joke…OnBioVC 1Q10 Trend [...]

Some interesting news out of the backyard here in Boulder, Colorado is that Nobel Prize winner Tom Cech, Ph.D. has been appointed as Special Advisor to the Morgenthaler Ventures Life Science Team, assisting Partners in the identification and review of new investment opportunities. Dr. Cech stepped down as President of the Howard Hughes Medical Institute [...]